PMID- 31103824
OWN - NLM
STAT- MEDLINE
DCOM- 20200106
LR  - 20200106
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 116
DP  - 2019 Aug
TI  - Ameliorative effects of pre-eclampsia by quercetin supplement to aspirin in a rat 
      model induced by L-NAME.
PG  - 108969
LID - S0753-3322(19)30671-7 [pii]
LID - 10.1016/j.biopha.2019.108969 [doi]
AB  - As an inflammatory disease, pre-eclampsia is correlated with elevation of 
      pro-inflammatory cytokines and maternal endothelial dysfunction. Aspirin plays an 
      important role in the prevention and therapy of pre-eclampsia. Quercetin is a 
      bioflavonoid which has anti-oxidant and reno-protective abilities. We aimed to 
      figure out the effects of quercetin supplement to aspirin on the therapy against 
      pre-eclampsia. Female pregnant Sprague-Dawley rats were divided into five groups 
      according to the drug treatment. Aspirin [1.5 mg/kg body weight (BW)] or 
      quercetin (2 mg/kg BW) treatment was administered from gestational day (GD) 4 to 
      GD19. Rat model of pre-eclampsia was induced by NG-nitro-Larginine-methyl-ester 
      (L-NAME). In pre-eclampsia rats induced by L-NAME, systolic blood pressures 
      (SBP), proteinuria, malonyldialdehyde (MDA), and inflammatory cytokines levels 
      were decreased by the treatment of quercetin supplement to aspirin. In the 
      uterus, quercetin supplement to aspirin prevented the expression of VEGF and 
      sFlt-1 mRNA. The treatment of quercetin supplement to aspirin rescued the 
      declined survival rate and weight of pups caused by L-NAME-induced pre-eclampsia. 
      Based on our study, compared with the treatment of aspirin alone, quercetin 
      supplement to aspirin enhanced the therapeutic effects of aspirin on 
      pre-eclampsia rats induced by L-NAME.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Yang, Shuangyan
AU  - Yang S
AD  - Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou, 061001, Hebei, 
      China. Electronic address: yshy1979@163.com.
FAU - Song, Lili
AU  - Song L
AD  - Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou, 061001, Hebei, 
      China.
FAU - Shi, Xiaofeng
AU  - Shi X
AD  - Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou, 061001, Hebei, 
      China.
FAU - Zhao, Na
AU  - Zhao N
AD  - Cangzhou Women and Children's Hospital, No. 92 Fuyang North Avenue, Cangzhou 
      Canal District, Cangzhou, 061001, Hebei, China.
FAU - Ma, Yaxin
AU  - Ma Y
AD  - Cangxian Hospital, No. 52 Huanghe East Road, Xinhua District, Cangzhou, 061000, 
      Hebei, China.
LA  - eng
PT  - Journal Article
DEP - 20190516
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Cytokines)
RN  - 0 (Inflammation Mediators)
RN  - 0 (RNA, Messenger)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 9IKM0I5T1E (Quercetin)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
RN  - R16CO5Y76E (Aspirin)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Cytokines/blood
MH  - *Dietary Supplements
MH  - Disease Models, Animal
MH  - Female
MH  - Inflammation Mediators/metabolism
MH  - Lipid Peroxidation/drug effects
MH  - NG-Nitroarginine Methyl Ester
MH  - Placenta/metabolism/pathology
MH  - Pre-Eclampsia/*chemically induced/*drug therapy/physiopathology
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Proteinuria/complications/physiopathology
MH  - Quercetin/pharmacology/*therapeutic use
MH  - RNA, Messenger/genetics/metabolism
MH  - Rats, Sprague-Dawley
MH  - Systole/drug effects
MH  - Uterus/drug effects/metabolism
MH  - Vascular Endothelial Growth Factor A/genetics/metabolism
MH  - Vascular Endothelial Growth Factor Receptor-1/genetics/metabolism
OTO - NOTNLM
OT  - Aspirin
OT  - NG-nitro-L-arginine-methyl-ester
OT  - Pre-eclampsia
OT  - Quercetin
EDAT- 2019/05/20 06:00
MHDA- 2020/01/07 06:00
CRDT- 2019/05/20 06:00
PHST- 2019/02/15 00:00 [received]
PHST- 2019/04/30 00:00 [revised]
PHST- 2019/05/08 00:00 [accepted]
PHST- 2019/05/20 06:00 [pubmed]
PHST- 2020/01/07 06:00 [medline]
PHST- 2019/05/20 06:00 [entrez]
AID - S0753-3322(19)30671-7 [pii]
AID - 10.1016/j.biopha.2019.108969 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2019 Aug;116:108969. doi: 10.1016/j.biopha.2019.108969. Epub 
      2019 May 16.